Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05637879
PHASE2/PHASE3

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

Sponsor: White River Junction Veterans Affairs Medical Center

View on ClinicalTrials.gov

Summary

A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).

Official title: Randomized Controlled Trial of Glecaprevir/Pibrentasvir for the Treatment of Post-traumatic Stress Disorder

Key Details

Gender

All

Age Range

19 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

92

Start Date

2023-12-18

Completion Date

2026-09-30

Last Updated

2025-04-24

Healthy Volunteers

No

Conditions

Interventions

DRUG

Glecaprevir/pibrentasvir

Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection

OTHER

Placebo

Compounded, inactive pill equal in appearance to active study drug

Locations (1)

White River Junction VAMC

White River Junction, Vermont, United States